Zhao J, He H, Jia Y, Zhang Y, Tian M
J Int Med Res. 2024; 52(11):3000605241275880.
PMID: 39568254
PMC: 11580049.
DOI: 10.1177/03000605241275880.
Cao H, Ma X
J Inflamm Res. 2024; 17:6765-6780.
PMID: 39364118
PMC: 11448468.
DOI: 10.2147/JIR.S477708.
Xiong F, Pula D, Akpek E, Bunya V, Shiboski C, Lietman T
Invest Ophthalmol Vis Sci. 2024; 65(1):23.
PMID: 38193760
PMC: 10784845.
DOI: 10.1167/iovs.65.1.23.
Mehta N, Emami-Naeini P
J Ophthalmic Vis Res. 2022; 17(2):276-289.
PMID: 35765634
PMC: 9185190.
DOI: 10.18502/jovr.v17i2.10804.
Jan R, Ho C, Wang J, Tseng S, Chang Y
J Pers Med. 2022; 12(1).
PMID: 35055420
PMC: 8778815.
DOI: 10.3390/jpm12010105.
Rituximab Therapy for Primary Sjögren's Syndrome.
Chen Y, Wang X, Jin X, Yang Z, Xu J
Front Pharmacol. 2021; 12:731122.
PMID: 34539411
PMC: 8445329.
DOI: 10.3389/fphar.2021.731122.
Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.
Sota J, Girolamo M, Frediani B, Tosi G, Cantarini L, Fabiani C
Ophthalmol Ther. 2021; 10(4):777-813.
PMID: 34476773
PMC: 8589879.
DOI: 10.1007/s40123-021-00393-8.
Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease.
Ng C, Sy A, Cunningham Jr E
J Ophthalmic Inflamm Infect. 2021; 11(1):24.
PMID: 34448063
PMC: 8390731.
DOI: 10.1186/s12348-021-00253-3.
Rituximab for non-infectious Uveitis and Scleritis.
Ng C, Sy A, Cunningham Jr E
J Ophthalmic Inflamm Infect. 2021; 11(1):23.
PMID: 34396463
PMC: 8364894.
DOI: 10.1186/s12348-021-00252-4.
Health system wide "big data" analysis of rheumatologic conditions and scleritis.
Berkenstock M, Carey A
BMC Ophthalmol. 2021; 21(1):14.
PMID: 33407267
PMC: 7788757.
DOI: 10.1186/s12886-020-01769-3.
Mycophenolate for the Treatment of Primary Sjögren's Syndrome.
Chen W, Lin J
J Transl Int Med. 2020; 8(3):146-149.
PMID: 33062590
PMC: 7534498.
DOI: 10.2478/jtim-2020-0023.
Commentary: Rituximab in scleritis.
Dutta Majumder P
Indian J Ophthalmol. 2020; 68(9):1983-1985.
PMID: 32823450
PMC: 7690482.
DOI: 10.4103/ijo.IJO_896_20.
Sjögren's Syndrome: More Than Just Dry Eye.
Akpek E, Bunya V, Saldanha I
Cornea. 2019; 38(5):658-661.
PMID: 30681523
PMC: 6482458.
DOI: 10.1097/ICO.0000000000001865.
Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study.
You C, Lamba N, Lasave A, Ma L, Diaz M, Foster C
Graefes Arch Clin Exp Ophthalmol. 2017; 255(6):1221-1228.
PMID: 28154932
DOI: 10.1007/s00417-017-3603-3.
Biologic therapy for refractory scleritis: a new treatment perspective.
de Fidelix T, Vieira L, de Freitas D, Trevisani V
Int Ophthalmol. 2015; 35(6):903-12.
PMID: 26319144
DOI: 10.1007/s10792-015-0124-0.
The Prevalence of Dry Eye Syndrome's and the Likelihood to Develop Sjögren's Syndrome in Taiwan: A Population-Based Study.
Yen J, Hsu C, Li Y, Hsu M
Int J Environ Res Public Health. 2015; 12(7):7647-55.
PMID: 26184245
PMC: 4515681.
DOI: 10.3390/ijerph120707647.
Pharmacotherapy of scleritis: current paradigms and future directions.
Beardsley R, Suhler E, Rosenbaum J, Lin P
Expert Opin Pharmacother. 2013; 14(4):411-24.
PMID: 23425055
PMC: 3888795.
DOI: 10.1517/14656566.2013.772982.
Biologic agents in inflammatory eye disease.
Posarelli C, Arapi I, Figus M, Neri P
J Ophthalmic Vis Res. 2012; 6(4):309-16.
PMID: 22454752
PMC: 3306110.
A case of necrotizing keratoscleritis in primary Sjogren's syndrome.
Choi W, Lee S, Park Y, Yoon K
Korean J Ophthalmol. 2011; 25(4):275-7.
PMID: 21860576
PMC: 3149140.
DOI: 10.3341/kjo.2011.25.4.275.
Ocular manifestation of rheumatoid arthritis-different forms and frequency.
Zlatanovic G, Veselinovic D, Cekic S, Zivkovic M, dordevic-Jocic J, Zlatanovic M
Bosn J Basic Med Sci. 2010; 10(4):323-7.
PMID: 21108616
PMC: 5489043.
DOI: 10.17305/bjbms.2010.2680.
